TW200408408A - Pharmaceutical compositions comprising ACAT inhibitor and insuline-resistance reducing agent - Google Patents
Pharmaceutical compositions comprising ACAT inhibitor and insuline-resistance reducing agent Download PDFInfo
- Publication number
- TW200408408A TW200408408A TW092107687A TW92107687A TW200408408A TW 200408408 A TW200408408 A TW 200408408A TW 092107687 A TW092107687 A TW 092107687A TW 92107687 A TW92107687 A TW 92107687A TW 200408408 A TW200408408 A TW 200408408A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- pharmacologically acceptable
- acceptable salt
- arteriosclerosis
- patent application
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 46
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 37
- 239000003638 chemical reducing agent Substances 0.000 title abstract 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 26
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims description 76
- 206010022489 Insulin Resistance Diseases 0.000 claims description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 44
- -1 1-octyl-5-carboxymethyl-4 , 6-Dimethylindolin-7-yl Chemical group 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 27
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 7
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 claims description 7
- 208000014644 Brain disease Diseases 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 claims description 5
- XYHAZQCTATWYDN-UHFFFAOYSA-N n-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-2-[4-[2-([1,3]oxazolo[4,5-b]pyridin-2-ylsulfanyl)ethyl]piperazin-1-yl]acetamide Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)CN1CCN(CCSC=2OC3=CC=CN=C3N=2)CC1 XYHAZQCTATWYDN-UHFFFAOYSA-N 0.000 claims description 5
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 claims description 5
- SIHFCVXQGXGQQO-UHFFFAOYSA-N 1-cyclohexyl-1-[[4-[[cyclohexyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]cyclohexyl]methyl]-3-[4-(dimethylamino)phenyl]urea Chemical compound C1=CC(N(C)C)=CC=C1NC(=O)N(C1CCCCC1)CC1CCC(CN(C2CCCCC2)C(=O)NC=2C=CC(=CC=2)N(C)C)CC1 SIHFCVXQGXGQQO-UHFFFAOYSA-N 0.000 claims description 4
- LUACLLSCZRRTIH-UPHRSURJSA-N 2-[[4-[(z)-4-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]but-2-enoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione Chemical compound O1C(=O)NC(=O)N1CC(C=C1)=CC=C1OC\C=C/COC(C=C1)=CC=C1CN1C(=O)NC(=O)O1 LUACLLSCZRRTIH-UPHRSURJSA-N 0.000 claims description 4
- WMUIIGVAWPWQAW-UHFFFAOYSA-N 2-ethoxy-3-[4-(2-phenoxazin-10-ylethoxy)phenyl]propanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OC2=CC=CC=C21 WMUIIGVAWPWQAW-UHFFFAOYSA-N 0.000 claims description 4
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 claims description 4
- AZKFGOQRYCSQPK-UHFFFAOYSA-N 5-[(7-phenylmethoxyquinolin-3-yl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CN=C(C=C(OCC=2C=CC=CC=2)C=C2)C2=C1 AZKFGOQRYCSQPK-UHFFFAOYSA-N 0.000 claims description 4
- FQCUYGFIIAZMLU-UHFFFAOYSA-N 5-[[2-(naphthalen-2-ylmethyl)-1,3-benzoxazol-5-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(OC(CC=2C=C3C=CC=CC3=CC=2)=N2)C2=C1 FQCUYGFIIAZMLU-UHFFFAOYSA-N 0.000 claims description 4
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims description 4
- XCMUCRXXBCAKCO-UHFFFAOYSA-N 1-benzyl-3-[6-methyl-2,4-bis(methylsulfanyl)pyridin-3-yl]-1-[[3-(1h-pyrazol-5-yl)phenyl]methyl]urea Chemical compound CSC1=CC(C)=NC(SC)=C1NC(=O)N(CC=1C=C(C=CC=1)C=1NN=CC=1)CC1=CC=CC=C1 XCMUCRXXBCAKCO-UHFFFAOYSA-N 0.000 claims description 3
- WUEHURHTEPWPPO-QZTJIDSGSA-N [4-[(4r,5r)-2-[[[2,6-di(propan-2-yl)phenyl]carbamoylamino]methyl]-4,5-dimethyl-1,3-dioxolan-2-yl]phenyl] dihydrogen phosphate Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC1(C=2C=CC(OP(O)(O)=O)=CC=2)O[C@H](C)[C@@H](C)O1 WUEHURHTEPWPPO-QZTJIDSGSA-N 0.000 claims description 3
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 claims description 3
- 206010034567 Peripheral circulatory failure Diseases 0.000 claims description 2
- KRMKZDOWCOBWNU-UHFFFAOYSA-N n-[2,6-di(propan-2-yl)phenyl]-2-tetradecylsulfanylacetamide Chemical compound CCCCCCCCCCCCCCSCC(=O)NC1=C(C(C)C)C=CC=C1C(C)C KRMKZDOWCOBWNU-UHFFFAOYSA-N 0.000 claims description 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 34
- 239000004480 active ingredient Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 229940126062 Compound A Drugs 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 239000004129 EU approved improving agent Substances 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003836 peripheral circulation Effects 0.000 description 4
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000001765 aortic valve Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OBSFXHDOLBYWRJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-[3-fluoro-4-(1h-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C(=O)NC=2C=C(F)C(OC=3C=4C=CNC=4N=CC=3)=CC=2)=CC=C1 OBSFXHDOLBYWRJ-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRJAITBRURLGCX-UHFFFAOYSA-N 1,2-oxazolidin-5-one Chemical compound O=C1CCNO1 ZRJAITBRURLGCX-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- UUDALWDRIFYZPM-UHFFFAOYSA-N 1h-pyridine-2,4-dione Chemical compound O=C1CC(=O)C=CN1 UUDALWDRIFYZPM-UHFFFAOYSA-N 0.000 description 1
- DMNKXKHLUXAYPK-UHFFFAOYSA-N 2,2-dimethylpropanamide Chemical compound [CH2]C(C)(C)C(N)=O DMNKXKHLUXAYPK-UHFFFAOYSA-N 0.000 description 1
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
- BVQFXKIUXBVUTC-UHFFFAOYSA-N 2-benzylprop-2-enylbenzene Chemical group C=1C=CC=CC=1CC(=C)CC1=CC=CC=C1 BVQFXKIUXBVUTC-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- BMHWGNHBBOIZMK-UHFFFAOYSA-N 3-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CN1C(=O)CSC1=O BMHWGNHBBOIZMK-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CLYMRXIXIOOVOL-UHFFFAOYSA-N 4-amino-2-propylbenzoic acid Chemical compound CCCC1=CC(N)=CC=C1C(O)=O CLYMRXIXIOOVOL-UHFFFAOYSA-N 0.000 description 1
- BBMFSGOFUHEVNP-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC(O)=CC=C1C(O)=O BBMFSGOFUHEVNP-UHFFFAOYSA-N 0.000 description 1
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
- TXHMJOYVFNDGMQ-UHFFFAOYSA-N 6-methoxy-1-methylbenzimidazole Chemical compound COC1=CC=C2N=CN(C)C2=C1 TXHMJOYVFNDGMQ-UHFFFAOYSA-N 0.000 description 1
- 241001659321 ANME-2 cluster Species 0.000 description 1
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000021411 American diet Nutrition 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 101100012465 Caenorhabditis elegans fce-2 gene Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- AZTUEPFJFVKYLD-UHFFFAOYSA-N [Na].C(C)OC(=O)C1=C(C=CC=C1)S Chemical compound [Na].C(C)OC(=O)C1=C(C=CC=C1)S AZTUEPFJFVKYLD-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- SIHFCVXQGXGQQO-WXUXXXNLSA-N chembl2397475 Chemical group C1=CC(N(C)C)=CC=C1NC(=O)N(C1CCCCC1)C[C@@H]1CC[C@@H](CN(C2CCCCC2)C(=O)NC=2C=CC(=CC=2)N(C)C)CC1 SIHFCVXQGXGQQO-WXUXXXNLSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- IGRIVAWLJUPVMM-UDEWTJCRSA-N methyl n-[(2s)-2-[4-[5-[4-[[(2s)-2-[(3s)-3-amino-2-oxopiperidin-1-yl]-2-cyclohexylacetyl]amino]phenyl]pentoxy]phenyl]-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@@H](C(=O)NC2=CC=C(C=C2)CCCCCOC2=CC=C(C=C2)[C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC)N2C([C@@H](N)CCC2)=O)CCCCC1 IGRIVAWLJUPVMM-UDEWTJCRSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical class C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- PFPYHYZFFJJQFD-UHFFFAOYSA-N oxalic anhydride Chemical compound O=C1OC1=O PFPYHYZFFJJQFD-UHFFFAOYSA-N 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical group N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000013875 sodium salts of fatty acid Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
200408408 .... . ... ........... ..... (發明說明應敘明:發明所屬之技術領域、先前技術、內容、實施方式及圖式簡單說明) 【發明所屬之技術領域】 本發明係相關於一種爲要預防或治療動脈硬化症或缺 血性心臟疾病、缺血性腦疾病或末梢循環衰竭症等由動脈 硬化引起的疾病之醫藥組成物,其方法係同時或相隔一段 時間給予醯基輔酶A ··膽固醇醯基轉換酶(以下簡稱爲ACAT 。)抑制劑及胰島素抵抗性改善劑。 又’本發明亦相關於將ACAT抑制劑及胰島素抵抗性改 善劑而成之醫藥組成物的藥理性有效量同時或相隔一段時 間給藥於溫血動物(特別是人類),藉此預防或治療動脈 硬化症或缺血性心臟疾病.、缺血性腦疾病或末梢循環衰竭 症等由動脈硬化引起的疾病之方法。 【先前技術】 隨著飲食歐美化和人口高齡化等,動脈粥樣硬化症急 速增加。動脈粥樣硬化症係缺血性心臟疾病(心肌梗塞、 狹心症、缺血性猝死)、缺血性腦疾病(腦梗塞、腦出血 等)、末梢循環衰竭症等的主因。又,引起動脈粥樣硬化 症的危險因素例如高血脂症(特別是高血膽固醇症)之外 ,高血壓症、胰島素抵抗性由來的糖代謝異常等。又,這 些危險因素常以合倂症(症候群X)的方式發病,例如高 血脂症不僅爲動脈硬化的危險因素亦容易引起黃色腫,進 行動脈硬化時會出現黃色腫,常引發心肌梗塞等血管合倂 -6- 200408408 症,彼此的病因會相互連結。{糖尿病,第3 7卷,第1 5 9 5 頁(1 9 8 8 年)「Diabetes · 3 7,1595(1988) ]},尋求其 有效的預防法及治療法。 至今,藉著倂用德羅克力達宗、匹歐克力達宗等胰島 素抵抗性改善劑和AC AT抑制劑,對治療阿茲海默病有助益 (W099 / 3 8498號公報),惟,無揭示有關藉著倂用ACAT 抑制劑和胰島素抵抗性改善劑,對動脈硬化進展抑制效果 及發生於四肢關節部的黃色腫之抑制效果如何。 【發明內容】 本發明者們計畫硏究動脈硬化症等的治療劑之結果, 發現由ACAT抑制劑及胰島素抵抗性改善劑而成之醫藥組成 物’相較於單獨給予各種藥劑,藉著同時或相隔一段時間 各別給予上述2劑,具有優異的對動脈硬化進展抑制效果 及發生於四肢關節部的黃色腫之抑制效果,因毒性弱故對 溫血動物(特別是人類),有助於動脈硬化症或缺血性心 臟疾病、缺血性腦疾病、末梢循環衰竭症等動脈硬化引發 的疾病之預防藥或治療藥(特別是治療藥),而完成本發 明。 本發明係相關於 (1 ) 一種醫樂組成物’其特徵係同時或相隔一段時間各 別給予ACAT抑制劑及胰島素抵抗性改善劑,可預防或治療 動脈硬化症或動脈硬化引發的疾病。 上述醫藥組成物中,較理想爲 (2 ) ACAT 抑制劑係 FR - 1 29 1 69、CI - 101 1、F - 1 3,94、F - 1 25 1 1 200408408 、T-2591、FCE-28654、K- 10085、HL-004、ΝΤΕ -122、FR - 186054 、N- ( 1-戊基-4,6 -二甲基吲哚啉-7-基)-2, 2 -二甲基丙醯 胺或N - ( 1 -辛基-5 -羧甲基-4,6 -二甲基吲哚啉-7 -基)-2,2 -二甲基丙醯胺或其藥理上可使用的鹽之醫藥組成物, (3 ) ACAT 抑制劑係 CI - 101 1、F - 1251 1、N - ( 1 -戊基-4,6-二甲基吲哚啉-7-基)-2, 2 -二甲基丙醯胺或N-( 1-辛基- 5-竣甲基-4, 6 - 一甲基D引噪啉-7-基)-2, 2 -二甲基丙醯胺或其 藥理上可使用的鹽之醫藥組成物。 (4 ) ACAT抑制劑係Ν - ( 1 -辛基-5 -羧甲基-4,6 -二甲基 吲哚啉-7 -基)-2,2 -二甲基丙醯胺或其藥理上可使用的鹽 之醫藥組成物, (5 ) 胰島素抵抗性改善劑係匹歐克力達宗、羅地克力達 宗、GI-262570、JTT-501、AZ-242、MCC- 5 5 5、YM- 440、KRP-297 、T-174、NC-2100、NN-622、BMS - 2 9 8 5 8 5 或 5-[4- (6-甲 氧基-1-甲基苯并咪唑-2-基甲氧基)苄基]噻唑啶-2, 4-二 酮或其藥理上可使用的鹽之醫藥組成物, (6 ) 胰島素抵抗性改善劑係匹歐克力達宗、羅地克力達 宗、或 5-[4-(6 -甲氧基-1-甲基苯并咪唑-2-基甲氧基) 苄基]噻唑啶-2,4 -二酮或其藥理上可使用的鹽之醫藥組 成物,或 (7 ) 胰島素抵抗性改善劑係5 - [ 4 - ( 6 -曱氧基-1 -甲基苯 并咪唑-2 -基甲氧基)苄基]噻唑啶-2,4 -二酮或其藥理上 可使用的鹽之醫藥組成物等。 又,從(2 ) - ( 4 )中選擇有效成分的AC AT抑制劑, 一 8- 200408408 從(5 ) - ( 7 )中選擇有效成分的胰島素抵抗性改善劑,在 這些物質中任意的組合所得之醫藥組成物亦適用,例如有 下列的組合方式。
(8) 有效成分的ACAT抑制劑係,FR- 1 29 1 69、CI>l〇U 、F-1394、F-12511、T-2591、FCE- 28 6 54、K-10085、HL-〇〇4 、NTE-122、FR-186054、N-( 1-戊基-4,6-二甲基吲哚咐_7、 基)-2,2-二甲基丙醯胺或1^-(1-辛基-5_羧甲基-4,6_二 甲基吲哚啉-7-基)-2, 2 -二甲基丙醯胺或其藥理上可使用 的鹽之醫藥組成物, 有效成分的胰島素抵抗性改善劑係匹歐克力達宗、羅 地克力達宗、GI_262570、JTT-501、AZ-242、MCC-555、YM-440 、KRP- 2 9 7、T-174、NC-2100、NN- 622、BMS- 298 5 8 5 或 5-[4~ (6 -甲氧基-1-甲基苯并咪唑-2-基甲氧基)苄基]噻哩口定 -2,4 -二酮或其藥理上可使用的鹽之醫藥組成物, (9 ) 有效成分的A C A T抑制劑係c I - 1 〇 Π、F - 1 2 5 1 1、N ~ (1-戊基-4,6 -二甲基吲哚啉-7-基)-2, 2 -二甲基丙醯胺或 1^-(1-羊基-5-殘甲基-4,6-二甲基口引[1朵啉_7-基)_2,2-二 甲基丙醯胺或其藥理上可使用的鹽之醫藥組成物。 有效成分的胰島素抵抗性改善劑係匹歐克力達宗、羅 地克力達宗、或5-[4-(6 -甲氧基甲基苯并咪唑-2_基 甲氧基)苄基]噻唑啶-2, 4 -二酮或其藥理上可使用的鹽 之醫藥組成物, (10)有效成分的ACAT抑制劑係N-( 1-辛基-5_羧甲基_4,6一 一甲基吲哚啉-7-基)-2, 2 -二甲基丙醯胺或其藥理上可使 9 200408408 用的鹽之醫藥組成物。 有效成分的胰島素抵抗性改善劑係5 - [ 4 - ( 6 -甲氧基_ 1-甲基苯并咪唑-2-基甲氧基)苄基]噻唑啶-2, 4 -二酮或 其藥理上可使用的鹽之醫藥組成物。 本發明的醫藥組成物的有效成分之一「AC AT抑制劑」 係一種抑制醯基輔酶A :膽固醇醯基轉換酶(AC AT )之藥 劑,其結果不僅降低膽固醇,亦直接作用於血管壁的動脈 硬化病變,因可抑制巨D筮細胞的泡沬細胞化(蓄積細胞內 的膽固醇),故使用爲動脈硬化症的治療藥或預防藥。這 類的ACAT抑制劑例如, W092 / 09 56 1號公報記載的含一般式(I )的化合物[較 理想爲FR - 1 2 9 1 6 9,其化學名爲N - ( 1,2 -苯基乙基)-2 -( 2 -辛基羥基苯基)乙醯胺。]、 特表平8-510256號公報(WO94/26702號公報或美國 特許第5 , 49 1,1 72號公報)記載的含一般式(I )的化合物 或其藥理上可使用的鹽丨較理想爲C I - 1 〇 1 1,其化學名爲 2,6 -二異丙基苯基- N- [(2,4,6 -三異丙基苯基)乙醯基]胺 磺酸鹽,本發明的C I - 1 〇 1 1亦含其藥理上可使用之鹽。}、 EP公開第42 1 44 1號公報(美國特許第5, 1 20, 7 3 8號 公報)中記載的含一般式(I )的化合物或其藥理上可使用 的鹽{較理想爲F - 1 3 94,其化學名爲(IS,2S ) - 2- [ 3 - ( 2,2-二甲基丙基)-3 -壬基脲基]環己烷-1 -基 3 - [ ( 4R ) ( 2,2, 5,5-四甲基-1,3 -一曙院-4-叛基)胺基]丙酸鹽,本發 明的F - 1 3 9 4亦含其藥理上可使用之鹽。)、 200408408 特表2000 - 5007 7 1號公報(w〇9 7 / 1 9 9 1 8號公報或美國 特g午第5,9 9 0,1 7 3號公報)記載的化合物或其藥理上可使 用的鹽[較理想爲F - 1 2 5 1 1,其化學名爲(s ) - 2,,3,,5,-三 甲基- 4’-羥基十二基硫苯基乙醯替苯胺,本發明的 F-12511亦含其藥理上可使用之鹽。]、 特開平1 0 - 1 9 5 0 3 7號公報(ΕΡ特許第7 9 0 2 4 0號公報 或美國特許第5,849 , 7 3 2號公報)記載的含一般式(I )的 化合物或其藥理上可使用的鹽[較理想爲Τ - 2 5 9 1,其化學 名爲1- ( 3 -第三丁基-2-經基-5-甲氧基苯基)-3- ( 2 -環 己基乙基)-3 - (4 -二甲基胺基苯基)脲,本發明的Τ-2591 亦含其藥理上可使用之鹽(鹽酸鹽等)。]、 W09 6 / 26 948號公報記載的含一般式(I )的化合物或 其藥理上可使用的鹽[較理想爲FCE- 286 54,其化學名爲1 _ (2,6-二異丙基苯基)-3-[(41^,5"-4,5-二甲基-2-(4-磷苯基)-1 , 3 -二氧雜環戊烷-2 -基甲基]脲,本發明的 FCE- 2 86 5 4 亦包含其藥理上可使用之鹽(鈉鹽等)。]、 W098 /54 153號公報(ΕΡ特許第9 87 2 5 4號公報)記載 的含一般式(I )的化合物或其藥理上可使用的鹽[較理想 爲Κ-10085,其化學名爲Ν-[2,4 -二(甲基硫)-6 -甲基- 3-吡啶基]-2 - [ 4 - [ 2 - ( Pf唑酮[4 , 5 - b ]吡啶-2 -基硫)乙基] 哌阱-1 -基]乙醯胺,本發明的K- 1 0085亦包含其藥理上可 使用之鹽。]、 W0 92 / 09 5 7 2號公報(EP特許第5 5 98 9 8號公報或美國 特許第5 , 4 7 5,1 3 0號公報)記載的含一般式(I )的化合物[ 200408408 較理想爲HL - 0 0 4,其化學名爲N - ( 2,6 -二異丙基苯基)-2 -十四基硫代乙醯胺。]、 特開平7 - 8 2 2 3 2號公報(EP特許第7 1 8 2 8 1號公報) 記載的含一般式(I )的化合物或其藥理上可使用的鹽{較 理想爲ΝΤΕ - 122,其化學名爲反式1,4 -二[1-環己基- 3- ( 4-二甲基胺基苯基)脲基甲基]環己烷,本發明的ΝΤΕ - 122亦 含其藥理上可使用之鹽(鹽酸鹽等)。)、 特表平10 - 5 1 051 2號公報(W09 6 / 1 05 5 9號公報)記載 的化合物或其藥理上可使用的鹽{較理想爲FR - 1 8 6 0 5 4,其 化學名爲1-苄基吡唑-3-基)苄基]-3-[2,6 -二( 甲基硫)-4 -甲基吡啶-3 -基]脲,本發明的FR - 1 8 6 0 5 4亦含 其藥理上可使用之鹽。}、 W09 6 / 09287號公報(ΕΡ特許第07 829 86號公報或美國 特許第5,9 90,1 50號公報)記載的含一般式(I )的化合物 或其藥理上可使用的鹽[較理想爲Ν -(卜戊基-4 , 6 -二甲基 吲哚啉-7 -基)-2 , 2 -二甲基丙醯胺,本發明亦含其藥理上 可使用之鹽。]、 W097 / 1 2860號公報(ΕΡ特許第08 6605 9號公報或美國 特許第6,0 6 3 , 8 0 6號公報)記載的含一般式(I )的化合物 或其藥理上可使用的鹽[較理想爲Ν -(卜辛基-5 -羧甲基-4,6 -二甲基吲哚啉-7 -基)-2,2 -二甲基丙醯胺,本發明亦 含其藥理上可使用之鹽(鹽酸鹽、硫酸鹽等),較理想爲 Ν-( 1-辛基-5-羧甲基-4, 6 -二甲基吲哚啉-7-基)-2, 2 -二 甲基丙醯胺·硫酸鹽。]。 -12- 200408408 這類 AC AT抑制劑中,較理想爲FR- 1 2 9 1 6 9、CI-1011 、F-1394、 F-12511 、 T-2591 、 FCE-28654、 K-10085、 HL-004 、ΝΤΕ - 1 22、FR- 1 8 6 0 5 4、N - ( 1 -戊基-4,6 -二甲基吲哚啉-7 -基)-2,2 -二甲基丙醯胺或N-(l -辛基-5-羧甲基-4, 6 -二 甲基吲哚啉-7 -基)-2,2 -二甲基丙醯胺, 更理想爲 C I - 1 0 1 1、F - 1 2 5 1 1、N - ( 1 -戊基-4 , 6 -二甲 基吲哚啉-7 -基)-2,2 -二甲基丙醯胺或N - ( 1 -辛基-5 -羧 甲基-4,6 -二甲基吲哚啉-7 -基)-2,2 -二甲基丙醯胺, 最理想爲N - ( 1 -辛基-5 -羧甲基-4 , 6 -二甲基吲哚啉-7-基)-2, 2 -二甲基丙醯胺。 下列爲理想的ACAT抑制劑的平面化學結構式。 200408408
F R - 1 2 9 1 6 9 C I - 1 〇 1 1
T一 2 5 9 1
-14- 200408408
ch3
N - ( 1 -戊基-4 - 6 -二甲基吲哚啉 -7 -基)-2,2 -二甲基丙醯胺 200408408
N-(1_辛基-5-羧甲基- 4,6·_二甲 基吲哚啉-7 -基)-2,2 -二甲基醯胺 本發明的醫藥組成物中有效成分之一的「胰島素抵抗 性改善劑」係藉著增強負責傳達胰島素受体的信號的酪胺 酸基酶之活性’提高胰島素作用的敏感性’藉由供應不足 之作用機制改善胰島素抵抗性之藥劑’至今使用爲糖尿病 用劑。這類的胰島素抵抗性改善劑例如’ 特開昭6 1 - 2 6 7 5 8 0號公報(EP特許第1 9 3,2 5 6號公報 或美國特許第4,68 7,7 7 7號公報)記載的含一般式(I )的 化合物或其藥理上可使用的鹽{較理想爲,匹歐克力達宗其 化學名爲5 - [ 4 - [ 2 - ( 5 -乙基-吡啶-2 -基)乙氧基]苄基]_ 2, 4-噻唑啶二酮,本發明的匹歐克力達宗亦含其藥理上可 使用之鹽(鹽酸鹽)。}、 特表平9 - 5 1 2 249號公報(W09 5 / 2 1 608號公報或美國 特許第5,002,9 5 3號公報)記載的含一般式(I )的化合物 或其藥理上可使用的鹽{較理想爲,羅地克力達宗其化學名 爲5 - [ 4 - [ 2 - ( N -甲基-N - 2 -吡啶醯胺)乙氧基]苄基卜2 4 _ 噻哗啶二酮,本發明的羅地克力達宗亦含其藥理上可使用 -16- 200408408 之鹽(馬來酸鹽等)。}、 w〇00 / 80 02號公報記載的含一般式(I )的化合物、其 藥理上可使用的鹽{較理想爲,G I - 2 6 2 5 7 0其化學名爲2 ( s )-(2 -苯醯基苯基胺基)-3-[4-[2-(5 -甲基-2-苯基-噚 唑基-4 -基)乙氧基]苯基]丙酸.,本發明的G I - 2 6 2 5 7 0亦 含其藥理上可使用之鹽(鹽酸鹽等)。}、 W09 5 / 1 8 1 25號公報(EP公開第684,242號公報或美國 特許第5,728 , 720號公報)記載的含一般式(I )的化合物 或其藥理上可使用的鹽{較理想爲J TT - 5 0 1,其化學名爲4 -[4-[2-(5 -甲基-2-苯基-噚唑基-4-基)乙氧基]苄基]3, 5-異噚唑啶二酮,本發明的JTT-501亦含其藥理上可使用之 鹽(鹽酸鹽等)。)、 W099 / 62872號公報(EP公開第1,084,103號公報或美 國特許第6,2 5 8,8 5 0號公報)記載的含一般式(I )的化合 物、其藥理上可使用的鹽{較理想爲AZ - 2 4 2,其化學名爲2 -乙氧基- 3- [4-[2- (4 -甲基磺醯羥基苯基)乙氧基]苯基]丙 酸,本發明的AZ- 242亦含其藥理上可使用之鹽(鈉鹽等) 〇卜 特開平6 - 247 945號公報(EP公開第6 0 4,9 8 3號公報 或美國特許第5,5 9 4,0 1 6號公報)記載的含一般式(I )的 化合物或其藥理上可使用的鹽{較理想爲MCC - 5 5 5,其化學 名爲5-[6- (2 -氟苄基羥基)萘基-2-基甲基]噻唑啶- 2,4-二酮,本發明的MCC-555亦含其藥理上可使用之鹽。}、 W09 4 / 25 448號公報(EP特許第6 9 6,5 8 5號公報或美國 200408408 特許第5,6 4 3 , 9 3 1號公報)記載的含—般式(I )的化合物 或其藥理上可使用的鹽{較理想爲ΥΜ_44〇,其化學名爲(Z )-1,4 -二[4 - ( 3,5 -二氧代-1,2,4 -噚二噻唑啶-2 -基甲基 )苯氧基]-2 - 丁烯,本發明的YM - 4 4 0亦含其藥理上可使用 之鹽。}、 特P平1 0 - 8 7 6 4 1號公報(美國特許第5 , 9 4 8,8 0 3號公 報)記載的含一般式(I )的化合物或其藥理上可使用的鹽 {較理想爲KRP- 2 97,其化學名爲5 - ( 2,4-二氧代噻唑啶- 5-基甲基)-2 -甲氧基-N- (4 -三氟甲基苄基)苯并醯胺,本 發明的KRP-297亦含其藥理上可使用之鹽。)、 特開昭6 4 - 5 6 6 7 5號公報(EP特許第2 8 3 0 3 5號公報或 美國特許第4,8 9 7,3 9 3號公報)記載的含一般式(I )的化 合物或其藥理上可使用的鹽{較理想爲T _ 1 7 4,其化學名爲 5-[2-(2-萘基甲基)-5-苯并噚唑基甲基]_2,4-噻唑啶二 嗣’本發明的T - 1 7 4亦含其藥理上可使用之鹽(鹽酸鹽) 〇卜 特開平9 - 1 0 0 2 8 0號公報(EP公開第7 8 7 7 2 5號公報或 大:國特I午第5,6 9 3,6 5 1號公報)記載的含一般式(I )的化 合物或其藥理上可使用的鹽[較理想爲NC - 2 1 0 0,其化學名 爲5 - ( 7 -苄氧基-3 -喹啉甲基)-2,4 -噻唑啶二酮,本發明 的NC - 2 1 0 0亦含其藥理上可使用之鹽(鹽酸鹽)。]、 W09 9 / 1 9 3 1 3號公報(美國特許第6,〇 5 4 , 4 5 3號公報) 5己載的含一般式(I )的化合物或其藥理上可使用的鹽{較 理想爲NN - 6 2 2,其化學名爲(s ) - 3 - [ 4 - [ 2 -(啡噚畊-1〇一 - 1 8 - 200408408 基)乙氧基]-苯基]-2 -乙氧基丙酸,本發明的NN-622亦含 其藥理上可使用之鹽(鈉鹽)。}、 W001/21602 5虎公碑記滅的含一般式(I)的化合物或 其藥理上可使用的鹽{較理想爲,BM S - 2 9 8 5 8 5其化學名爲N _ (4 -甲氧基苯氧基羰基)-N-[4-[2-(5 -甲基-2-苯基-4-喂 唑基)乙氧基卜苄基]甘胺酸,本發明的BMS- 29 8 5 8 5亦含 其藥理上可使用之鹽(鹽酸鹽)。}、 特開平9-295970號公報(美國特許第5,886,014號公 報)記載的含一般式(I )的化合物或其藥理上可使用的鹽 {較理想爲5-[4-(6 -甲氧基-1-甲基苯并咪唑-2-基甲氧基 )苄基]噻唑啶-2 ,4 -二酮,亦含其藥理上可使用之鹽(鹽 酸鹽)。}類的噚唑化合物、噚二唑啶化合物、噻唑啶化合 物或啡噚畊化合物,較理想爲匹歐克力達宗、羅地克力達 宗、GI-262570、JTT-501、AZ-242、MCC-555、YM-440、KRP-297 、T-174、NC-2100、NN-622、BMS- 298 5 8 5 或 5- [4- (6 -甲 氧基-1-甲基苯并咪唑-2-基甲氧基)苄基]噻唑啶-2, 4 -二 酮,更理想爲匹歐克力達宗、羅地克力達宗或5 - [ 4 - ( 6 -甲氧基-1-甲基苯并咪唑-2-基甲氧基)苄基]噻唑啶-2, 4-二酮,最理想爲5 - [ 4 - ( 6 -甲氧基-1 -甲基苯并咪唑-2 -基 甲氧基)苄基]噻唑啶-2,4 -二酮。 下列爲理想的胰島素抵抗性改善劑之平面化學結構式 -19- 200408408
π
-20- 200408408
-21 200408408
5-[4-(6 -甲氧基-1-甲基苯并咪唑- 2-基甲氧基);基]噻卩坐D定-2,4-二酮 上述「藥理上可使用之鹽」係有效成分的ACAT抑制劑 及/或胰島素抵抗性改善劑在含有如胺基等鹼性基時與酸反 應,或在含有如羧基等酸性基時與鹼反應,藉此形成的鹽 〇 以鹼基爲基礎之鹽例如氟氫酸鹽、鹽酸鹽、溴氫酸鹽 、碘氫酸鹽等鹵氫酸鹽、硝酸鹽、過氯酸鹽、硫酸鹽、磷 酸鹽等無機酸鹽;甲磺酸鹽、三氟甲磺酸鹽、乙磺酸鹽等 低級鏈烷磺酸鹽、苯磺酸鹽、對甲苯磺酸鹽等芳基磺酸鹽 、醋酸鹽、蘋果酸鹽、富馬酸鹽、琥珀酸鹽、檸檬酸鹽、 抗壞血酸鹽、酒石酸鹽、草酸鹽、馬來酸鹽等有機酸鹽; 及甘胺酸鹽、離胺酸鹽、精胺酸鹽、鳥胺酸鹽、谷胺酸鹽 、天冬胺酸鹽等胺基酸鹽,較理想爲鹽酸鹽、硫酸鹽、醋 酸鹽、富馬酸鹽、琥珀酸鹽或馬來酸鹽。 另一方面,以酸基爲基礎之鹽例如鈉鹽、鉀鹽、鋰鹽 等鹼金屬鹽、鈣鹽、鎂鹽等鹼土類金屬、鋁鹽、鐵鹽等金 屬鹽;銨鹽等無機鹽、叔辛胺鹽、二苄基胺鹽、嗎啉鹽、 -22- 200408408 葡糖胺鹽、苯甘胺酸烷基酯鹽、乙二胺鹽、N_甲基葡萄糖 胺鹽、胍鹽、二乙胺鹽、三乙胺鹽、二環己胺鹽、N,N、二 苄基乙一胺鹽、氯普魯卡因鹽、普魯卡因鹽、二乙醇胺鹽 、N -卞基本乙胺鹽、暧畊鹽、四甲鞍鹽、三(羥甲基)胺 基甲烷鹽般有機鹽等胺鹽;及甘胺酸鹽、離胺酸鹽、精胺 酸鹽、鳥胺酸鹽、谷胺酸鹽、天冬胺酸鹽等胺基酸鹽,更 理想爲鈉鹽、鉀鹽、鈣鹽、鎂鹽或鋁鹽。 上述「溶劑合物」係製造、精製時使用於有效成分的 ACAT抑制劑及/或胰島素抵抗性改善劑之溶劑,例如水、 醇等經過附加者,只要對ACAT抑制劑及/或胰島素抵抗性 改善劑無不良影響即可無特別的限制。上述「溶劑合物」 ’亦包括將AC AT抑制劑及/或胰島素抵抗性改善劑放置於 大氣中,吸收水分使吸附水附著而生成的水合物。較理想 的溶劑化物例如水合物。 本發明的醫藥組成物之有效成分AC AT抑制劑及/或胰 島素抵抗性改善劑,其分子內若含有不對稱碳原子時則有 各種異構物。本發明的化合物中這些異構物及這些異構物 的混合物已經以單一式表示。因此,本發明亦包括這些異 構物及這些異構物的任何比例之混合物。 由本發明的AC AT抑制劑及/或胰島素抵抗性改善劑而 成的醫藥組成物,係爲要同時或相隔一段時間個別給予 ACAT抑制劑及/或胰島素抵抗性改善劑之醫藥組成物。 本發明中,使用個別單劑的ACAT抑制劑及/或胰島素 抵抗性改善劑較二者倂用時具有優異的效果。又,ACAT抑 200408408 制劑和胰島素抵抗性改善劑若同時存在於体內未必能具有 這樣的效果。亦即,ACAT抑制劑和胰島素抵抗性改善劑即 使在血中不同時含有某種程度以上的濃度亦具有效果。臨 床上同時給予ACAT抑制劑和胰島素抵抗性改善劑較方便, 因此AC AT抑制劑和胰島素抵抗性改善劑可利用掺合劑的型 態給藥。在製劑,技術方面,若無法物理性地同時混合二製 劑時’亦可同時給予個別的單劑。又,即使非同時給予ACAT 抑制劑和胰島素抵抗性改善劑亦具有優異的效果,因此亦 可相隔適當的時間相繼給予個別的單劑。 亦即,本發明中同時給藥係可在幾乎相同的時間給藥 之給藥型態即可無特別的限制,惟以單一的組成物型態給 藥較理想。 本發明中相隔一段時間個別給藥係可在不同時間個別 給藥的給藥型態即可無特別的限制,例如首先給予ACAT抑 制劑,其次經過規定的時間後給予胰島素抵抗性改善劑, 或首先給予胰島素抵抗性改善劑,其次經過規定的時間後 給予ACAT抑制劑。本發明中,爲要達成ACAT抑制劑和胰 島素抵抗性改善劑產生的優異效果,上述2藥劑系統的給 藥間隔時間之極限可利用臨床或動物實驗進行確認。 本發明的醫藥組成物的有效成分之一 ACAT抑制劑,可 依據例如W09 2 / 09 5 6 1號公報、特表平8 - 5 1 02 5 6號公報( W094 / 2 67 02號公報、美國特許第5 ,491,172號公報)、EP 公開42 1 44 1號公報(美國特許第5, 1 2 0, 7 3 8號公報)、特 表200 0 - 5 07 7 1號公報(W097 / 1 9 9 1 8號公報、美國特許第 200408408 5 , 9 9 0,1 7 3號公報)、特開平1 0 - 1 9 5 0 3 7號公報(EP特許 第 7 90240號公報、美國特許第 5,849, 7 3 2號公報)、 W0 96 /26 9 4 8 號公報、W098 / 5 4 1 5 3 號公報(EP 特許第 9 8 7 2 5 4 號公報)、W09 2 / 0 9 5 7 2號公報(EP特許第5 5 9 89 8號公報 、美國特許第5,4 7 5,1 3 0號公報)、特開平7 - 8 2 2 3 2號公 報(EP特許第7 1 8 2 8 1號公報)、特表平1 0 - 5 1 0 5 1 2號公 報(W09 6 / 1 0 5 5 9號公報)、W096 / 09287號公報(EP特許 第 078298 6號公報、美國特許第 5,9 90, 1 50號公報)、 W097 / 1 2860號公報(EP特許第08 66 0 5 9號公報、美國特許 第6,06 3, 806號公報)等記載的方法容易地進行製造。 又,本發明的醫藥組成物的有效成分之一胰島素抵抗 性改善劑,可依據例如特開昭6 1 - 26 7 5 80號公報(EP特許 第1 9 3 2 5 6號公報、美國特許第4 , 6 8 7,7 7 7號公報)、特表 平 9 - 5 1 2249號公報(W09 5 / 2 1 608號公報、美國特許第 5,002,9 5 3 號公報)、WO00 / 8002 號公報、W09 5 / 1 8 1 25 號 公報(EP公開第684242號公報、美國特許第5,7 28,720 號公報)、W09 9 / 6 2 8 7 2號公報(EP公開第1 0 8 4 1 0 3號公報 、美國特許第6,25 8,8 5 0號公報)、特開平6 - 247 945號公 報(EP公開第60498 3號公報、美國特許第5,5 9 4 , 0 1 6號 公報)、W094/25448號公報(EP特許第696,585號公報、 美國特許第5,64 3,931號公報)、特開平1 0 - 8764 1號公報 (美國特許第5 , 948,80 3號公報)、特開昭64 - 5 66 7 5號公 報(EP特許第2 8 3 0 3 5號公報、美國特許第4 , 8 7 9,3 9 3號 公報)、特開平9 - 1 002 8 0號公報(EP公開第7 8 7 72 5號公 200408408 報、美國特許第5,6 9 3 , 6 5 1號公報)、WO 9 9 / 1 9 3 1 3號公報 (美國特許第6 , 0 5 4,4 5 3號公報)、W00 1 / 2 1 602號公報、 特開平9- 29 5 9 70號公報(美國特許第5,88 6,014號公報) 等記載的方法容易地進行製造。 【實施方式】 下列以實例及製劑例更詳細地說明本發明,惟本發明 的範圍不受限於此。 實例1 大動脈病變面積的測定 分別設置1 2週齡雄性且缺乏阿樸脂蛋白E的小白鼠作 爲對照群、5 - [ 4 - ( 6 -甲氧基-1 -甲基苯并咪唑-2 -基甲氧基 )苄基]噻唑啶-2,4 -二酮·鹽酸鹽(0 · 0 0 0 1重量%混餌。 以下簡稱爲化合物B )給藥群、N - ( 1 -辛基-5 -羧甲基-4,6 -二甲基吲哚啉-7-基)-2, 2 -二甲基丙醯胺·硫酸鹽(0.03 重量%混餌。以下簡稱爲化合物A )給藥群、及化合物B ( 0 . 000 1重量%混餌)/化合物A ( 0 · 03重量%混餌)倂用群 等4群(各群10例),將藥物混餌給予1 2週。第1 2週時 解剖動物,求出大動脈瓣膜動脈硬化病變面積和巨噬細胞 (抗M0MA-2染色陽性部)面積率。 (1 )動脈硬化病變面積 在大動脈瓣膜進行彈性樹膠三色染色法,計測動脈硬 化病變面積。 動脈硬化病變面積少者,其抗動脈硬化作用強,顯示 具有抑制動脈硬化進行之效果。 -26- 200408408 (2 )巨噬細胞面積率 在大動脈瓣膜進行抗Μ0ΜΑ - 2染色’計測巨噬細胞面積 、 (抗Μ0ΜΑ - 2染色陽性部面積),算出相對於動脈硬化病變 面積之面積率。 巨噬細胞係病變(噬菌斑)的不安定化因子,巨噬細 胞的減少和噬菌斑的安定化相關,其具有抗動脈硬化作用 。因此,巨噬細胞面積率小者,其噬菌斑的安定化作用進 而抗動脈硬化作用強,顯示具有抑制動脈硬化進行之效果 〇 表1所示爲(1 )及(2 )的結果。表1中的實測値係 以平均値±標準誤差來表示。 (表1 ) 給藥群 動脈硬化病變(#m2) 巨噬細胞面積率(% ) 對照群 127246± 20950 20.2± 3.6 化合物B給藥群 80616± 11611 23.3土 4.1 化合物A給藥群 654961 ± 15344 13.7± 2.2 化合物B+化合物A倂用群 70467 ± 12132 2.8± 0·62 -27- 1 依據鄧肯氏多項比較試驗相對於對照群的顯著性差異爲 p S 0 , 0 5。 2 * 1 )依據鄧肯氏多項比較試驗相對於對照群的顯著性差異 爲 p S 0 · 0 1。 200408408 製劑例1 錠劑 化合物B 50 _ ,〇mg 化合物A 10 . Omg 乳糖 11 : ).Omg 玉米丨殿粉 25 · Omg 硬脂酸鎂 2 . 0 m r 200 mg 將上 述處方的粉末混合 ,使用打錠機打錠成1錠 200 >mg 的錠劑。 又, 上述處方中化合物 A係表不 爲N- (1 -辛基 -5 - 羧 甲基-4 , 6 -二甲基吲哚啉—7 _ 基)-2,2- 二甲基丙醯胺 •硫 酸 鹽,化合 物B係表示爲5 _ [ 4 - ( 6 -甲氧基-1 -甲基苯并咪 唑 -2 -基甲氧基)苄基]噻唑啶 -2,4-二酮 •鹽酸 鹽〇 【應用在產業上的可能性】
本發明的由ACAT抑制劑及胰島素抵抗性改善劑而成之 醫藥組成物具有優異的動脈硬化進展抑制效果及對發病於 四肢關節部的黃色腫之發病抑制效果,且毒性弱,可作爲 溫血動物(特別是人)的動脈硬化症或缺血性心臟疾病、 缺血性腦疾病或末梢循環衰竭症等動脈硬化引起的疾病之 預防藥或治療藥。 如上所述,本發明的醫藥組成物之有效成分AC AT抑制 劑和胰島素抵抗性改善劑可以單獨的個別單位給藥型態, 或混合調製成物理性1個的單位給藥型態。 200408408 本發明的醫藥組成物作爲上述疾病的預防藥或治療藥 時’可將各個本發明的醫藥組成物之有效成分ACAT抑制劑 及胰島素抵抗性改善劑或與藥理上可接受的賦形劑、稀釋 劑等混合’製成錠劑、膠囊劑、顆粒劑、散劑或糖漿劑等 以經口方式或注射劑或塞劑等非經口方式進行給藥。 這些製劑的製法係使用賦形劑(例如乳糖、白糖、葡 萄糖、甘露糖醇、山梨糖醇等糖衍生物;玉米澱粉、馬鈴 薯澱粉、α澱粉、糊精等澱粉衍生物;結晶纖維素等纖維 素衍生物;阿拉伯膠、葡聚糖、支鏈澱粉等有機類賦形劑 ;及輕質矽酸酐、合成矽酸鋁、矽酸鈣、甲基矽酸鋁酸鎂 等矽酸鹽衍生物;磷酸氫鈣等磷酸鹽;碳酸鈣等碳酸鹽; 硫酸鈣等硫酸鹽等無機類賦形劑等。)、潤滑劑(例如硬 脂酸、硬脂酸鈣、硬脂酸鎂等硬脂酸金屬鹽;滑石;膠体 二氧化矽;蜂膠、鯨蠘等蠟類;硼酸;己二酸;硫酸鈉等 硫酸鹽·’乙醇酸;富馬酸;苯甲酸鈉;DL亮胺酸;脂肪酸 鈉鹽,月桂基硫酸鈉、月桂基硫酸鎂等月桂基硫酸鹽;石夕 酸酐、矽酸水合物等矽酸類;及上述澱粉衍生物等。)、 黏合劑(例如邀丙基纖維素、翔丙基甲基纖維素、聚乙爆 Π比咯烷酮、聚乙二醇及與上述賦形劑相同之化合物等。) 、崩解劑(例如低取代度羥丙基纖維素、羯甲基纖維素、 羯甲基纖維素銘、內部交聯鑛甲基纖維素鈉等纖維素衍生 初,鑛甲基搬粉、羰甲基激粉鈉、交聯聚乙嫌啦咯院酮等 化學修飾丨殿粉•纖維素類等。)、安定劑(甲基對胺基苯 甲酸、丙基對胺基苯甲酸等對羥基苯甲酸醋類;氯丁醇、 -29- 200408408 节醇、苯乙醇等醇類;氯化苄烷胺;苯酚、甲酚等酚類; 乙基永硫代水楊酸鈉;脫氫乙酸;及山梨糖酸等。)、除 味去臭劑(例如一般使用的甘味劑、酸味劑、香料等。) 、稀釋劑等添加劑,以公知的方法進行製造。 本發明的醫藥組成物之有效成分ACAT抑制劑和胰島素 抵抗性改善劑之給藥量及給藥比率,係依各個藥劑的活性 、患者的症狀、年齡、體重等:各種條件而變化。 其給藥量依症狀、年齡等而異,經口給藥時1次用量 的下限爲O.lmg (較理想爲〇.5mg),上限爲l〇〇〇mg (較 理想爲5 00mg ),非經口給藥時1次用量的下限爲〇 . 〇img (較理想爲0 · 05mg ),上限爲l〇〇mg (較理想爲50mg ), 成人的用量1日爲1〜6次,可依症狀同時或相隔一段時間 個別給藥。 又,本發明的醫藥組成物之有效成分ACAT抑制劑和胰 島素抵抗性改善劑之給藥量的比率亦可大幅地變化,例如 ACAT抑制劑和胰島素抵抗性改善劑的給藥量比率在重纛比 1 : 5 0 0〜5 0 0 : 1之範圍內皆可。 -30-
Claims (1)
- 200408408 拾、申請專利範圍 1 · 一種醫藥組成物,其特徵係同時或相隔〜段時間各別給 予ACAT抑制劑及胰島素抵抗性改善劑,可預防或治療動 脈硬化症或動脈硬化引發的疾病。 2 .如申請專利範圍第1項之醫藥組成物,其中ACAT抑制劑 係 FR_129169、CI_1011、F_1394、F_125ll、T_2591、 FCE-28654、 K-10085、 HL-004、 NTE-122、 FR-186054、 N_ (1-戊基-4,6 - 一甲基卩引卩朵啉-7-基)-2,2 -二甲基丙釅胺 或N-( 1-辛基-5-羧甲基- 4,6-二甲基吲哚啉-7_基L2,2_ 二甲基丙醯胺或其藥理上可使用的鹽。 3 .如申請專利範圍第1項之醫藥組成物,其中ACAT抑制劑 係(:1-1011、^12511、!^(1-戊基-4,6-二甲基吲哚啉_ 7 -基)-2, 2 -二甲基丙醯胺或N-(l-辛基-5-羧甲基- 4,6-二甲基吲哚啉-7-基)-2,2 -二甲基丙醯胺或其藥理上可 使用的鹽。 4 .如申請專利範圍第1項之醫藥組成物,其中ACAT抑制劑 係N - ( 1 -辛基-5 -羧甲基-4 , 6 -二甲基吲哚啉-7 -基)-2 , 2 -二甲基丙醯胺或其藥理上可使用的鹽。 5 .如申請專利範圍第1〜4項中任一項之醫藥組成物,其中 胰島素抵抗性改善劑係匹歐克力達宗、羅地克力達宗、 GI-262570、 JTT-501 、 AZ-242、 MCC-555、 YM-440、 KRP-297、T-174、NC-2100、NN-622、BMS-298585 或 5 - [ 4 -( 6 -甲氧基-1 -甲基苯并咪唑-2 -基甲氧基)苄基]噻唑啶 -2,4 -二酮或其藥理上可使用的鹽。 -31- 200408408 6 ·如申請專利範圍第〗〜4項中任一項之醫藥組成物,其中 胰島素抵抗性改善劑係匹歐克力達宗、羅地克力達宗或 5-[4-(6 -甲氧基-1-甲基苯并咪唑-2-基甲氧基)苄基]噻 口坐D定-2,4 -二酮或其藥理上可使用的鹽。 7 ·如申請專利範圍第 1〜4項中任一項之醫藥組成物,其中 胰島素抵抗性改善劑係5 - [ 4 - ( 6 -甲氧基-卜甲基苯并咪 唑-2-基甲氧基)苄基]噻唑啶-2, 4 -二酮或其藥理上可使 用的鹽。 8 .如申g靑專利軔圍第1〜7項中任一項之醫藥組成物,其目 的係爲要預防或治療動脈硬化症。 9 ·如申請專利範圍第1〜7項中任一項之醫藥組成物,其目 的係爲要預防或治療因動脈硬化引發的疾病。 1 0 ·如申請專利範圍第9項之醫藥組成物,其中因動脈硬化 引發的疾病係缺血性心臟疾病。 1 1 ·如申請專利範圍第9項之醫藥組成物,其中因動脈硬化 引發的疾病係缺血性腦疾病。 1 2 ·如申請專利範圍第9項之醫藥組成物,其中因動脈硬化 引發的疾病係末梢循環衰竭症。 -32- 200408408 陸、(一)、本案指定代表圖爲:第__圖 (二)、本代表圖之元件代表符號簡單說明: Μ ^ \\\柒、本案若有化學式時,請揭示最能顯示發明特徵的化 .學式丨-4-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002103134 | 2002-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200408408A true TW200408408A (en) | 2004-06-01 |
Family
ID=28786290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092107687A TW200408408A (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical compositions comprising ACAT inhibitor and insuline-resistance reducing agent |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1493448A4 (zh) |
KR (1) | KR20040099394A (zh) |
CN (1) | CN1655822A (zh) |
AU (1) | AU2003236365A1 (zh) |
BR (1) | BR0308871A (zh) |
CA (1) | CA2481379A1 (zh) |
TW (1) | TW200408408A (zh) |
WO (1) | WO2003084572A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200600497A (en) * | 2001-02-02 | 2006-01-01 | Sankyo Co | Preparation of indoline derivative |
CA2560928A1 (en) * | 2004-03-29 | 2005-10-06 | Sankyo Company Limited | Therapeutic agent for diabetes containing insulin resistance improving agent |
ES2885698T3 (es) | 2009-06-25 | 2021-12-15 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos nh-ácidos |
CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ293016B6 (cs) * | 1995-06-01 | 2004-01-14 | Sankyo Company Limited | Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem |
DK0866059T3 (da) * | 1995-10-05 | 2002-03-25 | Kyoto Pharma Ind | Nye heterocykliske derivater og medicinsk anvendelse deraf |
CA2311356C (en) * | 1998-01-28 | 2004-07-13 | Warner-Lambert Company | Method for treating alzheimer's disease |
-
2003
- 2003-04-03 WO PCT/JP2003/004296 patent/WO2003084572A1/ja active Application Filing
- 2003-04-03 CA CA002481379A patent/CA2481379A1/en not_active Abandoned
- 2003-04-03 CN CNA038125676A patent/CN1655822A/zh active Pending
- 2003-04-03 EP EP03745697A patent/EP1493448A4/en not_active Withdrawn
- 2003-04-03 KR KR10-2004-7015748A patent/KR20040099394A/ko not_active Application Discontinuation
- 2003-04-03 BR BR0308871-5A patent/BR0308871A/pt not_active IP Right Cessation
- 2003-04-03 AU AU2003236365A patent/AU2003236365A1/en not_active Abandoned
- 2003-04-04 TW TW092107687A patent/TW200408408A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1493448A4 (en) | 2007-12-05 |
CA2481379A1 (en) | 2003-10-16 |
WO2003084572A1 (fr) | 2003-10-16 |
BR0308871A (pt) | 2005-01-04 |
AU2003236365A1 (en) | 2003-10-20 |
CN1655822A (zh) | 2005-08-17 |
EP1493448A1 (en) | 2005-01-05 |
KR20040099394A (ko) | 2004-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2275654T3 (es) | Combinaciones que contienen inhibidores de la dipeptidilpeptisada-iv y agentes antidiabeticos. | |
JP2022020624A (ja) | 心房拡大又はリモデリングを特徴とする疾患を治療するためのnep阻害剤 | |
JP7098214B2 (ja) | 非アルコール性脂肪性肝炎(NASH)の処置のためのsGC刺激物質の使用 | |
JPH08505605A (ja) | Tnf産生の阻害剤 | |
TWI680760B (zh) | 治療黑色素瘤的藥物組合 | |
TW200803861A (en) | Administration of dipeptidyl peptidase inhibitors | |
HRP20000327A2 (en) | Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor | |
KR20100101056A (ko) | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 | |
JP2005527510A (ja) | 癌の治療において一酸化窒素模倣体を使用するための製剤および方法 | |
TW201912153A (zh) | 用於治療b型肝炎的化合物、醫藥組合物及方法 | |
JP2005527523A (ja) | AngII介在性疾病を処置するための4−(4−メチルピペラジン−1−イルメチル)−N−[4−メチル−3−(4−ピリジン−3−イル)ピリミジン−2−イル−アミノ]フェニル]−ベンズアミド | |
TW200800212A (en) | Administration of dipeptidyl peptidase inhibitors | |
TW200408408A (en) | Pharmaceutical compositions comprising ACAT inhibitor and insuline-resistance reducing agent | |
JP2023506196A (ja) | 化合物及びα1-アンチトリプシン欠損症の治療のためのそれらの使用 | |
US20160324929A1 (en) | METHODS OF TREATING DISEASES ASSOCIATED WITH PPARy | |
KR20240055745A (ko) | 코로나바이러스 억제제 | |
JP2011526266A (ja) | 消化管の炎症状態の処置を目的とするオキサゾリジノン類 | |
US7351692B2 (en) | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | |
AU2002328569B9 (en) | Medicinal compositions containing angiotensin II receptor antagonist | |
JP2006509720A (ja) | 潰瘍治療用プロトンポンプ阻害剤としての環付加ピロール化合物 | |
US20050119314A1 (en) | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent | |
JP2004002365A (ja) | Acat阻害剤とインシュリン抵抗性改善剤とからなる医薬組成物 | |
TWI839690B (zh) | 治療黑色素瘤的藥物組合的用途 | |
JP2002128700A (ja) | 癌を予防及び治療するための医薬組成物 | |
JPH0449236A (ja) | ニカルジピン含有ホスホリパーゼa↓2阻害剤 |